<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924270</url>
  </required_header>
  <id_info>
    <org_study_id>20/3106</org_study_id>
    <nct_id>NCT04924270</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Faecal Microbiota Transplantation in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases</brief_title>
  <acronym>FRONT</acronym>
  <official_title>Safety and Clinical Efficacy Associated With Faecal Microbiota Transplantation Performed in Treatment-naïve Patients With Newly Diagnosed Rheumatoid Arthritis, Reactive Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Gouty Arthritis, Psoriasis, Hidradenitis Suppurativa, Pulmonary Sarcoidosis, Crohn's Disease, and Ulcerative Colitis: a 52-week, Double-blind, Randomised, Placebo-controlled, Exploratory Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torkell Ellingsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes are to explore clinical efficacy aspects, safety, and patient acceptability&#xD;
      associated with capsule faecal microbiota transplantation (cFMT) performed in newly&#xD;
      diagnosed, untreated patients with chronic inflammatory rheumatic-, dermatological-,&#xD;
      gastrointestinal- and pulmonary diseases.&#xD;
&#xD;
      In this double-blind, placebo-controlled, randomised, 52-week exploratory trial, 200 patients&#xD;
      with 10 different diagnoses of CIDs (n = 20 in each diagnosis stratum) fulfilling the study&#xD;
      criteria will be enrolled at time of diagnosis. The baseline visit will be performed as&#xD;
      quickly as possible (days) after the patient's informed consent has been obtained to ensure&#xD;
      no unnecessary treatment delay. Stratified by diagnosis, patients will be randomised (1:1) to&#xD;
      either placebo or cFMT provided from an anonymous healthy donor. The experimental&#xD;
      intervention cFMT/placebo will be repeated once weekly the following four weeks. In addition,&#xD;
      all participants will be offered the Danish national guideline first-line immunosuppressive&#xD;
      treatment following the baseline visit. At baseline, at 8 weeks (primary endpoint&#xD;
      evaluation), and at 52 weeks a clinical examination will be conducted and clinical scores and&#xD;
      patient-reported outcomes for each disease entity will be collected. All adverse events will&#xD;
      be registered throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the physical component score (PCS) of the 36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>8 weeks (+/- 1 week)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mental component score (MCS) of the 36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>8 weeks (+/- 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient global assessment (VAS 0-100 mm)</measure>
    <time_frame>8 weeks (+/- 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient fatigue (VAS 0-100 mm)</measure>
    <time_frame>8 weeks (+/- 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient pain (VAS 0-100 mm)</measure>
    <time_frame>8 weeks (+/- 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physician's global assessment (VAS 0-100 mm)</measure>
    <time_frame>8 weeks (+/- 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-reactive protein</measure>
    <time_frame>8 weeks (+/- 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the physical component score (PCS) of the 36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>52 weeks (+/- 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mental component score (MCS) of the 36-Item Short Form Health Survey</measure>
    <time_frame>52 weeks (+/- 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient global assessment (VAS 0-100 mm)</measure>
    <time_frame>52 weeks (+/- 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient fatigue (VAS 0-100 mm)</measure>
    <time_frame>52 weeks (+/- 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient pain (VAS 0-100 mm)</measure>
    <time_frame>52 weeks (+/- 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physician's global assessment (VAS 0-100 mm)</measure>
    <time_frame>52 weeks (+/- 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-reactive protein</measure>
    <time_frame>52 weeks (+/- 2 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Reactive Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Gouty Arthritis</condition>
  <condition>Psoriasis</condition>
  <condition>Hidradenitis Suppurativa</condition>
  <condition>Pulmonary Sarcoidosis</condition>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>cFMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Faecal microbiota transplantation</intervention_name>
    <description>The capsule FMT transplant consists of faeces obtained from a thoroughly screened, unpaid, anonymous stool donor. Each FMT product is made from 50g faeces diluted in sterile saline (0.9% NaCl) and glycerol, blended, centrifuged and filtered to remove particulate material before transfer to double-layered capsules. The FMT capsules will be stored at - 80 ⁰C until use. On the day of the FMT, the FMT capsules will be thawed to room temperature before treatment.</description>
    <arm_group_label>cFMT</arm_group_label>
    <other_name>capsule FMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules consist of NaCl (0.9%) and glycerol added brown food colouring.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosis of rheumatoid arthritis (RA), reactive arthritis (ReA), ankylosing&#xD;
             spondylitis (AS), psoriatic arthritis (PsA), psoriasis (Ps), gouty arthritis (GA),&#xD;
             hidradenitis suppurativa (HS), pulmonary sarcoidosis (PSar), Crohn's disease (CD), or&#xD;
             ulcerative colitis (UC).&#xD;
&#xD;
          -  Treatment-naïve which is defined as no current or previous disease-modifying&#xD;
             anti-rheumatic drugs or systemic immunosuppressive drugs including glucocorticoids.&#xD;
&#xD;
          -  Presence of treatment indication (no contra-indications) and patient accept to start&#xD;
             first-line treatment in accordance with the Danish national guideline for the specific&#xD;
             diagnosis following the baseline visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coeliac disease, food allergy or severe food intolerance.&#xD;
&#xD;
          -  Current cancer.&#xD;
&#xD;
          -  Hepatitis B and C, HIV, HTLV1/2, and active TB or other serious chronic infections.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Not wishing to participate or not suited for FMT intervention or project evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torkell Ellingsen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torkell Ellingsen, MD PhD</last_name>
    <phone>0045 6611 3333</phone>
    <email>torkell.ellingsen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maja S. Kragsnaes, MD PhD</last_name>
    <email>maja.kragsnaes@dadlnet.dk</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Torkell Ellingsen</investigator_full_name>
    <investigator_title>MD PhD, Clinical professor and head of research</investigator_title>
  </responsible_party>
  <keyword>Faecal microbiota transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Arthritis, Reactive</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Gouty</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available upon reasonable request. This will require review and approval by the trial scientific board and the data responsible parties. Terms of collaboration will be reached together with a signed collaboration agreement and data processor agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

